Bioventus
Bioventus develops innovations in pain treatment, restorative therapies, and surgical solutions to help patients resume active lives.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $415m | Post IPO Debt |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 34 % | 19 % | - | 12 % | (1 %) | 6 % | 4 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 12 % | 6 % | 12 % | 13 % | 20 % | 21 % | 22 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 4 % | (31 %) | (30 %) | (6 %) | 3 % | 5 % | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 5 % | 3 % | 2 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Bioventus Inc., established in 2012 and headquartered in Durham, NC, is a global leader in developing biologics and medical devices aimed at active healing. The company specializes in products that promote bone healing and provide relief from osteoarthritis pain. Bioventus serves a diverse range of clients, including healthcare providers and patients seeking non-drug solutions for chronic pain and bone-related conditions. Operating in the medical technology market, Bioventus generates revenue through the sale of its innovative products, which are known for their safety, effectiveness, and ability to improve patient outcomes. In 2022, Bioventus products helped over 600,000 people regain active lifestyles. The company's business model focuses on continuous innovation and partnerships to enhance its product portfolio and market reach. Key products include orthobiologics, biologics, and the StimRouter, a device that delivers electrical pulses to target chronic peripheral nerve pain.
Keywords: biologics, bone healing, osteoarthritis, pain relief, medical devices, chronic pain, orthobiologics, active lifestyles, healthcare, innovation.
Tech stack
Investments by Bioventus
Edit
